« Return to News | Drug Sponsors

Renovo cuts jobs after Shire partnership ends

Thursday, March 3, 2011 02:44 PM

U.K.-based Renovo has halted spending and says it will lay off 100 workers in a broad restructuring that includes the possible sale of virtually all of its clinical assets, according to Fierce Biotech.

Shire ended its $825 million partnership with Renovo, handing back the rights to the anti-scarring drug Juvista, according to a statement from Renovo. The company is shelving its own work on the drug after concluding, "the efficacy of Juvista is insufficient to demonstrate significant benefit when tested in a broad population of scar revision patients."

Renovo CEO Mark Ferguson said, "We are extremely surprised and disappointed with the Juvista phase III trial result in scar revision surgery.  The board is seeking to maximize shareholder value from the remaining assets of Renovo." The company also said it would curtail recruitment in an ongoing trial of another drug, Adaprev, and will consider selling that program along with Juvista, Juvidex, Prevascar and all of its preclinical assets.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.